Pirtobrutinib (also known as LOXO-305) is a medication that belongs to the class of BTK inhibitors. It works by blocking specific proteins that help cancer cells grow and survive. This medication is being studied as a new treatment option for patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Venetoclax is a medication that works by blocking a protein called BCL-2, which helps cancer cells survive. By blocking this protein, venetoclax can cause cancer cells to die. It is already approved for treating certain types of blood cancers.

Rituximab is an antibody therapy that targets specific proteins (CD20) found on the surface of certain blood cancer cells. It helps the immune system identify and destroy these cancer cells. Rituximab has been used for many years to treat various types of blood cancers and autoimmune conditions.

Chronic Lymphocytic Leukemia – A slow-growing blood cancer that starts in white blood cells called lymphocytes in the bone marrow. These abnormal cells gradually build up in the blood, bone marrow, and lymph nodes. The disease typically develops over months or years, with many people not showing symptoms in early stages. As it progresses, it can cause swollen lymph nodes, fatigue, and increased risk of infections. This condition sometimes occurs together with Small Lymphocytic Lymphoma, which is essentially the same disease but primarily affects the lymph nodes rather than the blood and bone marrow.

Small Lymphocytic Lymphoma – A type of cancer that affects the lymphocytes, a kind of white blood cell that helps the body fight infection. The disease mainly involves the lymph nodes, causing them to become enlarged. It is considered the same disease as Chronic Lymphocytic Leukemia but with a different pattern of where the cancer cells collect in the body. People with this condition may experience fatigue, night sweats, and unexplained weight loss.